Comparative Pharmacology
Head-to-head clinical analysis: UNIPEN IN PLASTIC CONTAINER versus VEETIDS 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNIPEN IN PLASTIC CONTAINER versus VEETIDS 125.
UNIPEN IN PLASTIC CONTAINER vs VEETIDS '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and peptidoglycan cross-linking.
VEETIDS '125' (presumed to be a formulation containing penicillin V potassium) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg intravenously or intramuscularly every 4-6 hours. Maximum dose 12 g per day.
125 mg orally twice daily for 5-10 days.
None Documented
None Documented
0.5-1 hour (normal renal function); prolonged to 2-5 hours in renal impairment
2-4 hours in patients with normal renal function (CrCl >80 mL/min); prolonged to 20-40 hours in anuria. Clinical note: dosing interval must be adjusted based on creatinine clearance to avoid accumulation.
Renal: 60-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minor, <10%
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic